InvestorsHub Logo

SAMNOTSAMUEL

01/03/18 4:42 PM

#29196 RE: andrius #29185

The problem is not seen as efficacy for the small OM market, the question is whether delcath is currently seen as commercially attractive. the company will be lucky to ever achieve $100 million revenue unless it can finish a robust ICC trial that may start soon